Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Access to healthcare

His Job Is to Sell a $1,000 Pill for $10 Without Losing Money

Editor's pick
Bloomberg
29 February 2016
Hepatitis C treatment

New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Editor's pick
World Health Organization
25 February 2016
People who inject drugs

Should we focus hepatitis C treatment on some injectors and not others?

Editor's pick
Drug & Alcohol Findings
22 February 2016
Pharmaceutical industry

The cost of curing Hepatitis C

Editor's pick
BBC Newsnight / You Tube
18 February 2016
Hepatitis C treatment

Hepatitis C virus relapse uncommon after sustained virological response

Editor's pick
Medscape
17 February 2016
Hepatitis C treatment

U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease

Editor's pick
Gilead press release
17 February 2016
Hepatitis C treatment

12 Feb 2016: My day of reckoning

Editor's pick
Hep Magazine
12 February 2016
Access to healthcare

Are States Obligated To Provide Expensive Hepatitis C Drugs?

Editor's pick
Kaiser Health News
10 February 2016
Hepatitis C treatment

New cases of hepatitis C in NYC are on the rise

Editor's pick
Politico
9 February 2016
Hepatitis C treatment

mapCrowd: an online data collection platform for hepatitis C information

Editor's pick
Treatment Action Group
9 February 2016
Hepatitis C treatment

Olysio/Sovaldi yield high SVR post-liver transplant

Editor's pick
Healio
8 February 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
New & experimental hepatitis C treatment

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Editor's pick
Bristol-Myers Squibb press release
8 February 2016
Hepatitis C treatment

Pennsylvania to Offer Free Hepatitis C Treatment to Low-Income People With HIV

Editor's pick
Poz magazine news
5 February 2016
Activism & civil society

Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs

Editor's pick
Seattle Times
3 February 2016
Hepatitis C treatment

Lawmaker: Costly hepatitis C drug "a slap in the face to veterans"

Editor's pick
CBS News
3 February 2016
Pharmaceutical industry

Merck Throws a Wrench in Drug Pricing

Editor's pick
Bloomberg
1 February 2016
Hepatitis C treatment

European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

Editor's pick
Bristol-Myers Squibb press release
1 February 2016
Hepatitis C treatment

Merck Prices Hepatitis C Drug Lower Than Rivals in Crowded Field

Editor's pick
Bloomberg
29 January 2016
Hepatitis C treatment

California Doles Out Millions to Insurers for Hepatitis C Drugs

Editor's pick
KQED News
29 January 2016
Hepatitis C treatment

Kansas Legislators Walk Back On Lifetime Ban For Hepatitis C Drugs

Editor's pick
KCUR
24 January 2016
New & experimental hepatitis C treatment

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

Editor's pick
AbbVie press release
11 January 2016
Hepatitis C treatment

The drug that costs more than $1200, and sells for $5 in India

Editor's pick
Sydney Morning Herald
3 January 2016
Drug interactions & pharmacokinetics

Many patients on new HCV medications at risk of drug-drug interactions

Editor's pick
Medscape (requires free registration)
23 December 2015